Genetic interactions with diet influence the risk of cardiovascular disease

American Journal of Clinical Nutrition

Volumn 83, Issue 2, 2006, Pages

  Ordovas, José M ^a,b,c  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

APOA1; APOA5; Apolipoprotein; Apolipoprotein A I; Apolipoprotein A V; Cardiovascular disease; Cardiovascular risk; HDL cholesterol; Polymorphism; Polyunsaturated fatty acids; Triacylglycerol

Indexed keywords

APOLIPOPROTEIN A1; ARACHIDONATE 5 LIPOXYGENASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; CHOLESTEROL; LIPOPROTEIN;

ALLELE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIET; DIETARY INTAKE; FAT INTAKE; GENE INTERACTION; HUMAN; LIPID METABOLISM; NUTRIGENOMICS; NUTRITIONAL STATUS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; CARDIOVASCULAR FUNCTION; GENETICS; METABOLISM; REVIEW; RISK FACTOR;

APOLIPOPROTEIN A-I; ARACHIDONATE 5-LIPOXYGENASE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CHOLESTEROL; DIET; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; LIPID METABOLISM; LIPOPROTEINS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 33644869190     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/83.2.443s     Document Type: Conference Paper

References (34)

1. American Heart Association. AHA scientific position: risk factors and coronary heart disease. Dallas, TX: American Heart Association, 2004.
2. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91.
3. Ye SQ, Kwiterovich PO Jr. Influence of genetic polymorphisms on responsiveness to dietary fat and cholesterol. Am J Clin Nutr 2000;72:1275S-84S.
4. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41.
5. Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992;69:1015-21.
6. Juo SH, Wyszynski DF, Beaty TH, Huang HY, Bailey-Wilson JE. Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta-analysis. Am J Med Genet 1999;82:235-41.
7. Matsunaga A, Sasaki J, Han H, et al. Compound heterozygosity for an apolipoprotein A1 gene promoter mutation and a structural nonsense mutation with apolipoprotein A1 deficiency. Arterioscler Thromb Vasc Biol 1999;19:348-55.
8. Jeenah M, Kessling A, Miller N, Humphries S. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990;7:233-41.
9. Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 1990;31:1371-7.
10. Meng QH, Pajukanta P, Valsta L, Aro A, Pietinen P, Tikkanen MJ. Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med 1997;241:373-8.
11. Paul-Hayase H, Rosseneu M, Robinson D, Van Bervliet JP, Deslypere JP, Humphries SE. Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum Genet 1992;88:439-46.
12. Xu CF, Angelico F, Del Ben M, Humphries S. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo AI levels in boys and girls. Genet Epidemiol 1993;10:113-22.
13. Saha N, Tay JS, Low PS, Humphries SE. Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol 1994;11:255-64.
14. Talmud PJ, Ye S, Humphries SE. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study. Genet Epidemiol 1994;11:265-80.
15. Sigurdsson G Jr, Gudnason V, Sigurdsson G, Humphries SE. Interaction between a polymorphism of the apo A-I promoter region and smoking determines plasma levels of HDL and apo A-I. Arterioscler Thromb 1992;12:1017-22.
16. Minnich A, DeLangavant G, Lavigne J, Roederer G, Lussier-Cacan S, Davignon J. G[rarror]A substitution at position -75 of the apolipoprotein A-I gene promoter. Evidence against a direct effect on HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1995;15:1740-5.
17. Kamboh MI, Aston CE, Nestlerode CM, McAllister AE, Hamman RF. Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. Atherosclerosis 1996;127:255-62.
18. Civeira F, Pocovi M, Cenarro A, Garces C, Ordovas JM. Adenine for guanine substitution -78 base pairs 5′ to the apolipoprotein (APO) A-I gene: relation with high density lipoprotein cholesterol and APO A-I concentrations. Clin Genet 1993;44:307-12.
19. Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994;35:1292-6.
20. Akita H, Chiba H, Tsuji M, et al. Evaluation of G-to-A substitution in the apolipoprotein A-I gene promoter as a determinant of high-density lipoprotein cholesterol level in subjects with and without cholesteryl ester transfer protein deficiency. Hum Genet 1995;96:521-6.
21. Needham EW, Mattu RK, Rees A, Stocks J, Galton DJ. A polymorphism in the human apolipoprotein AI promoter region: a study in hypertriglyceridaemic patients. Hum Hered 1994;44:94-9.
22. Peacock RE, Hamsten A, Johansson J, Nilsson-Ehle P, Humphries SE. Associations of genotypes at the apolipoprotein AI-CIII-AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses. Clin Genet 1994;46:273-82.
23. Wang XL, Liu SX, McCredie RM, Wilcken DE. Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996;98:372-7.
24. Sessler AM, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression. J Nutr 1998;128:923-6.
25. Mata P, Lopez-Miranda J, Pocovi M, et al. Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998;137:367-76.
26. Ordovas JM, Corella D, Cupples LA, et al. Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. Am J Clin Nutr 2002;75:38-46.
27. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50.
28. Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med Res Rev 2001;21:540-52.
29. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001;12:245-54.
30. Lacquemant C, Lepretre F, Pineda Torra I, et al. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab 2000;26:393-401.
31. Vohl MC, Lepage P, Gaudet D, et al. Molecular scanning of the human PPARα gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000;41:945-52.
32. Tai ES, Demissie S, Cupples LA, et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002;22:805-10.
33. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29-37.
34. Cogent Research, Cambridge, MA. Internet: www.cogentresearch.com.